We further identified regional variation in Ki-67 labeling index and FOXM1 immunofluorescence that correlated with tumor grade, with increased heterogeneity among spatially defined WHO grade II and grade III meningioma samples (Fig. 4d, e). This evidence concerns the gene MKI67 and neoplasm.